| pubmed-article:9625536 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C0011306 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C0042196 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C1517927 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:9625536 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:9625536 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9625536 | pubmed:dateCreated | 1998-7-9 | lld:pubmed |
| pubmed-article:9625536 | pubmed:abstractText | In order to enhance the antitumor vaccination effect of dendritic cells (DC) pulsed with class I tumor peptide, we tried to utilize the local cytokine help of CD4+ T cells reactive to a streptococcal preparation OK432. DC were prepared from murine bone marrow cells by culture with both granulocyte/macrophage-colony-stimulating factor and interleukin(IL)-4. The peritumoral injections of OK432 induced OK432-reactive CD4+ T cells in the draining lymph nodes, and their in vitro production of interferon gamma was thus significantly enhanced by restimulation with OK432-pulsed DC. In addition, anti-P815 mastocytoma cytotoxic T lymphocytes were generated from the in vivo OK432-treated P815-draining lymph node cells only when the lymph node cells were restimulated in vitro with the DC pulsed with both P1A peptide and OK432. Moreover, the peritumoral injections of OK432 and the subsequent vaccination of the DC, pulsed with both OK432 and P1A peptide, significantly suppressed the growth of s.c. inoculated P815. Interestingly, a significant level of IL-12 was detected in the coculture supernatant of both OK432-pulsed DC and OK432-reactive CD4+ T cells. Collectively, our results suggest that the antitumor vaccination effect of DC pulsed with class I tumor peptide could thus be effectively augmented by locally utilizing the Th1-type cytokines from OK432-reactive CD4+ T cells. | lld:pubmed |
| pubmed-article:9625536 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9625536 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9625536 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9625536 | pubmed:month | May | lld:pubmed |
| pubmed-article:9625536 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:AbeKK | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:LOJJ | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:NomotoKK | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:HaradaMM | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:TadaHH | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:TamadaKK | lld:pubmed |
| pubmed-article:9625536 | pubmed:author | pubmed-author:MeroK NKN | lld:pubmed |
| pubmed-article:9625536 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9625536 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:9625536 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9625536 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9625536 | pubmed:pagination | 128-36 | lld:pubmed |
| pubmed-article:9625536 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:meshHeading | pubmed-meshheading:9625536-... | lld:pubmed |
| pubmed-article:9625536 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9625536 | pubmed:articleTitle | Antitumor vaccination effect of dendritic cells can be augmented by locally utilizing Th1-type cytokines from OK432-reactive CD4+ T cells. | lld:pubmed |
| pubmed-article:9625536 | pubmed:affiliation | Department of Immunology, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. | lld:pubmed |
| pubmed-article:9625536 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9625536 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9625536 | lld:pubmed |
